FI3976581T3 - [2-(3-fluori-5-metaani-sulfonyylifenoksi)etyyli](propyli)amiinin viinihapposuolat - Google Patents
[2-(3-fluori-5-metaani-sulfonyylifenoksi)etyyli](propyli)amiinin viinihapposuolat Download PDFInfo
- Publication number
- FI3976581T3 FI3976581T3 FIEP20725728.8T FI20725728T FI3976581T3 FI 3976581 T3 FI3976581 T3 FI 3976581T3 FI 20725728 T FI20725728 T FI 20725728T FI 3976581 T3 FI3976581 T3 FI 3976581T3
- Authority
- FI
- Finland
- Prior art keywords
- formula
- salt
- tartaric acid
- formula iva
- pharmaceutical composition
- Prior art date
Links
- OSBPYFBXSLJHCR-UHFFFAOYSA-N n-[2-(3-fluoro-5-methylsulfonylphenoxy)ethyl]propan-1-amine Chemical class CCCNCCOC1=CC(F)=CC(S(C)(=O)=O)=C1 OSBPYFBXSLJHCR-UHFFFAOYSA-N 0.000 title 1
- 150000003892 tartrate salts Chemical class 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 10
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 239000002904 solvent Substances 0.000 claims 4
- 235000002906 tartaric acid Nutrition 0.000 claims 4
- 239000011975 tartaric acid Substances 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 239000002244 precipitate Substances 0.000 claims 2
- KYARBIJYVGJZLB-UHFFFAOYSA-N 7-amino-4-hydroxy-2-naphthalenesulfonic acid Chemical compound OC1=CC(S(O)(=O)=O)=CC2=CC(N)=CC=C21 KYARBIJYVGJZLB-UHFFFAOYSA-N 0.000 claims 1
- 235000011002 L(+)-tartaric acid Nutrition 0.000 claims 1
- 239000001358 L(+)-tartaric acid Substances 0.000 claims 1
- FEWJPZIEWOKRBE-LWMBPPNESA-N L-(+)-Tartaric acid Natural products OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- AUONNNVJUCSETH-UHFFFAOYSA-N icosanoyl icosanoate Chemical compound CCCCCCCCCCCCCCCCCCCC(=O)OC(=O)CCCCCCCCCCCCCCCCCCC AUONNNVJUCSETH-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 239000011877 solvent mixture Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C315/00—Preparation of sulfones; Preparation of sulfoxides
- C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19176514 | 2019-05-24 | ||
| EP20166361 | 2020-03-27 | ||
| PCT/EP2020/064046 WO2020239568A1 (en) | 2019-05-24 | 2020-05-20 | Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3976581T3 true FI3976581T3 (fi) | 2024-01-31 |
Family
ID=70682855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP20725728.8T FI3976581T3 (fi) | 2019-05-24 | 2020-05-20 | [2-(3-fluori-5-metaani-sulfonyylifenoksi)etyyli](propyli)amiinin viinihapposuolat |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US12275694B2 (enExample) |
| EP (2) | EP3976581B1 (enExample) |
| JP (1) | JP7623958B2 (enExample) |
| KR (1) | KR102892833B1 (enExample) |
| CN (1) | CN113853369B (enExample) |
| AU (1) | AU2020286003B2 (enExample) |
| BR (1) | BR112021023563A2 (enExample) |
| CA (1) | CA3140805A1 (enExample) |
| CL (1) | CL2021003115A1 (enExample) |
| CO (1) | CO2021016556A2 (enExample) |
| DK (1) | DK3976581T3 (enExample) |
| ES (2) | ES2970361T3 (enExample) |
| FI (1) | FI3976581T3 (enExample) |
| IL (1) | IL288271B2 (enExample) |
| JO (1) | JOP20210312A1 (enExample) |
| MX (1) | MX2021014271A (enExample) |
| PH (1) | PH12021552844A1 (enExample) |
| PL (1) | PL3976581T3 (enExample) |
| PT (1) | PT3976581T (enExample) |
| SG (1) | SG11202112165QA (enExample) |
| WO (1) | WO2020239568A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12275694B2 (en) | 2019-05-24 | 2025-04-15 | Irl 790 Ab | Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof |
| JP7688690B2 (ja) | 2020-07-28 | 2025-06-04 | スーチュアン・コールン－バイオテック・バイオファーマシューティカル・カンパニー・リミテッド | ピリミジン系化合物の塩、結晶形およびその調製方法 |
| JP2023548429A (ja) * | 2020-11-10 | 2023-11-16 | インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー | パーキンソン病、特にｌ－ｄｏｐａ誘発性ジスキネジアのための医薬品に対する感作の予防または軽減における使用のための［２－（３－フルオロ－５－メタンスルホニルフェノキシ）エチル］（プロピル）アミン（メスドペタム） |
| WO2024042540A1 (en) * | 2022-08-24 | 2024-02-29 | Alkem Laboratories Limited | Mesdopetam compositions |
| CA3268423A1 (en) | 2022-09-21 | 2024-03-28 | Assia Chemical Industries Ltd. | Solid state forms of mesdopetam and salts thereof |
| GB202312055D0 (en) | 2023-08-07 | 2023-09-20 | Ipsen Biopharm Ltd | Pharmaceutical compositions |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS51123821A (en) | 1975-04-18 | 1976-10-28 | Nippon Kayaku Co Ltd | An algicide and protective agent |
| US4128574A (en) * | 1976-10-04 | 1978-12-05 | General Electric Company | Method for making organic polycarboxylic acids |
| GB8823405D0 (en) | 1988-10-05 | 1988-11-09 | Erba Carlo Spa | Aryloxy-arythio-heteraryloxy-heteroarylthio-alkenylene derivatives of amines |
| ES2169102T3 (es) | 1994-10-14 | 2002-07-01 | Merck Patent Gmbh | (r)-(-)-2-(5-(4-fluorfenil)-3-piridilmetilaminometil)-cromano como agente activo sobre el sistema nervioso central. |
| SE9904723D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
| DOP2001000189A (es) | 2000-06-30 | 2002-03-30 | Pfizer Prod Inc | Benzofenonas y sulfonas como inhibidores de la captación de glicina |
| JP2006193494A (ja) | 2005-01-17 | 2006-07-27 | Dainippon Ink & Chem Inc | ４級アンモニウム系化合物を有効成分とする心臓疾患治療剤 |
| CN101203511A (zh) | 2005-06-23 | 2008-06-18 | 阿斯利康(瑞典)有限公司 | 作为神经激肽受体拮抗剂用于治疗胃肠疾病的新氮杂环丁烷衍生物 |
| WO2007063789A1 (ja) | 2005-11-29 | 2007-06-07 | Kissei Pharmaceutical Co., Ltd. | 新規なカテコール誘導体、それを含有する医薬組成物およびそれらの用途 |
| WO2007072041A1 (en) | 2005-12-23 | 2007-06-28 | Astex Therapeutics Limited | Therapeutic compounds |
| AU2007218086A1 (en) * | 2006-02-15 | 2007-08-30 | M's Science Corporation | Piperazine derivatives |
| CA2687721A1 (en) * | 2007-06-08 | 2008-12-18 | Arena Pharmaceuticals, Inc. | Crystalline forms of (r)-1-{2-[4'-(3-methoxy-propane-1-sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto |
| TW200932225A (en) * | 2007-12-14 | 2009-08-01 | Lundbeck & Co As H | 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine |
| JP2011519839A (ja) | 2008-04-29 | 2011-07-14 | エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ | ドーパミン神経伝達のモジュレーター |
| WO2009133110A1 (en) | 2008-04-29 | 2009-11-05 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Modulators of dopamine neurotransmission |
| MX2010011724A (es) | 2008-04-29 | 2010-11-30 | Nsab Af Neurosearch Sweden Ab | Moduladores de neurotransmision de dopamina. |
| US9006227B2 (en) * | 2011-04-19 | 2015-04-14 | Integrative Research Laboratories Sweden Ab | Modulators of cortical dopaminergic- and NMDA-receptor-mediated glutamatergic neurotransmission |
| WO2016106142A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
| MX391727B (es) | 2016-02-08 | 2025-03-21 | Merck Patent Gmbh | Modificaciones cristalinas de clorhidrato de n-(4,5-bismetansulfonil-2-metilbenzoil)guanidina y sales de n-(4,5-bismetansulfonil-2-metilbenzoil)guanidina. |
| EP3625213B1 (en) | 2017-05-19 | 2023-03-08 | Integrative Research Laboratories Sweden AB | (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine fumarate, a process for its preparation and uses thereof |
| SG11202000833YA (en) * | 2017-08-07 | 2020-02-27 | Suven Life Sciences Ltd | Fluoropiperidine compounds as pure 5-ht6 receptor antagonists |
| WO2020110128A1 (en) | 2018-11-29 | 2020-06-04 | Prilenia Neurotherapeutics Ltd. | Combination of pridopidine and an additional therapeutic agent for treating drug induced dyskinesia |
| US12275694B2 (en) | 2019-05-24 | 2025-04-15 | Irl 790 Ab | Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof |
-
2020
- 2020-05-20 US US17/612,902 patent/US12275694B2/en active Active
- 2020-05-20 PH PH1/2021/552844A patent/PH12021552844A1/en unknown
- 2020-05-20 KR KR1020217037818A patent/KR102892833B1/ko active Active
- 2020-05-20 FI FIEP20725728.8T patent/FI3976581T3/fi active
- 2020-05-20 DK DK20725728.8T patent/DK3976581T3/da active
- 2020-05-20 SG SG11202112165QA patent/SG11202112165QA/en unknown
- 2020-05-20 EP EP20725728.8A patent/EP3976581B1/en active Active
- 2020-05-20 CN CN202080036829.0A patent/CN113853369B/zh active Active
- 2020-05-20 EP EP23190702.3A patent/EP4292653B1/en active Active
- 2020-05-20 BR BR112021023563A patent/BR112021023563A2/pt unknown
- 2020-05-20 JP JP2021569359A patent/JP7623958B2/ja active Active
- 2020-05-20 PT PT207257288T patent/PT3976581T/pt unknown
- 2020-05-20 IL IL288271A patent/IL288271B2/en unknown
- 2020-05-20 PL PL20725728.8T patent/PL3976581T3/pl unknown
- 2020-05-20 AU AU2020286003A patent/AU2020286003B2/en active Active
- 2020-05-20 CA CA3140805A patent/CA3140805A1/en active Pending
- 2020-05-20 ES ES20725728T patent/ES2970361T3/es active Active
- 2020-05-20 WO PCT/EP2020/064046 patent/WO2020239568A1/en not_active Ceased
- 2020-05-20 MX MX2021014271A patent/MX2021014271A/es unknown
- 2020-05-20 ES ES23190702T patent/ES3072819T3/es active Active
-
2021
- 2021-11-24 JO JOP/2021/0312A patent/JOP20210312A1/ar unknown
- 2021-11-24 CL CL2021003115A patent/CL2021003115A1/es unknown
- 2021-12-06 CO CONC2021/0016556A patent/CO2021016556A2/es unknown
-
2025
- 2025-03-14 US US19/080,430 patent/US20250243155A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023203246B2 (en) | Methods of manufacturing benzoquinoline compounds | |
| US20230066720A1 (en) | Novel prodrugs and conjugates of dimethyltryptamine | |
| EP1256576B1 (en) | Fused imidazolium derivatives | |
| US6635630B2 (en) | Selective neurokinin antagonists | |
| EP2526094B1 (en) | Substituted chlorocyclopentanols for therapeutic applications | |
| AU743929B2 (en) | Morphinane derivatives and medicinal use thereof | |
| US20150353577A1 (en) | Method for producing (1s,4s,5s)-4-bromo-6-oxabicyclo[3.2.1]octan-7-one | |
| WO2017008773A1 (en) | Crystalline forms of obeticholic acid | |
| WO2019005841A1 (en) | THERAPEUTIC COMPOUNDS AND METHODS FOR TREATING INFECTION | |
| SG183243A1 (en) | Salt of fused heterocyclic derivative and crystal thereof | |
| WO2016016766A2 (en) | A process for the preparation of isavuconazonium or its salt thereof | |
| AU2018341782A1 (en) | Method for preparing oxaspirocycle derivative, and intermediate thereof | |
| IL288271B1 (en) | Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof | |
| CA2542140A1 (en) | Crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone | |
| CA3155875A1 (en) | BIARYL COMPOUND SUBSTITUTED BY SULFO OR CORRESPONDING SALT, METHOD FOR PREPARATION AND USE | |
| AU2011363636B2 (en) | Process for the production of a pemetrexed salt | |
| WO2019167085A1 (en) | Process for the preparation of (s)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino propanamide methanesulfonate | |
| WO2005092866B1 (en) | New derivatives of 4, 5, 6, 7-tetrabromobenzimidazole and method of their preparation | |
| CA3060086A1 (en) | Methods of preparing indolinobenzodiazepine derivatives | |
| HUT75091A (en) | Thienopyridon derivatives | |
| CN113979875B (zh) | 一种地佐辛衍生物晶型a及其制备方法和应用 | |
| EP3130589A1 (en) | Heterocyclic aza compounds | |
| TWI443100B (zh) | 培美曲塞鹽的製法 | |
| CN106187916B (zh) | 一种有效去除利匹韦林异构体的方法 | |
| CN111263764A (zh) | (r)-9-(2,5-二氟苯乙基)-4-乙基-2-甲基-1-氧杂-4,9-二氮杂螺[5.5]十一烷-3-酮的盐 |